Clinical Trial Finder

Inclusion Criteria:

• - Diagnosis of Essential Thrombocythemia per World Health Organization (WHO) diagnostic criteria for myeloproliferative neoplasms.

• - Requires treatment in order to lower platelet count based on patient age over 60 or history of thrombosis.

• - Have failed at least one standard therapy.

• - Must have discontinued ET therapy at least 1 week (4 weeks for interferon) prior to study drug initiation.

Exclusion Criteria:

• - Has undergone major surgery ≤4 weeks prior to starting study drug or has not recovered from side effects of such surgery.

• - Unresolved treatment related toxicities from prior therapies (unless resolved to ≤ Grade 1).

• - Uncontrolled active infection.

• - Current use of prohibited medications.

• - Known HIV infection or active Hepatitis B or Hepatitis C virus infection.

• - Other hematologic/biochemistry requirements, as per protocol.

• - Use of investigational agent within last 14 days.

- Pregnant or lactating females

This is a Phase 2 multi-center, open-label study evaluating the safety, efficacy and pharmacodynamics of IMG-7289 administered orally once daily in patients with essential thrombocythemia (ET). Patients will be dosed with IMG-7289 for 169 consecutive days in the Initial Treatment Period (ITP). Qualifying patients may continue to receive IMG-7289 in the Additional Treatment Period (ATP). Safety will be evaluated by clinical assessments of safety parameters i.e. safety laboratory testing, adverse event reporting, physical examination and vital sign assessments. Pharmacodynamics will be evaluated by hematology assessment, patient reported symptom burden, change in spleen size by palpation and other measures. To ensure safety, a Safety Advisory Board will perform periodic reviews of safety parameters and pharmacodynamic markers.

Arms

Experimental: IMG-7289

IMG-7289 administered daily for 169 consecutive days

Interventions

Drug: - IMG-7289

LSD1 inhibitor